B cells and antibodies in the defense against Mycobacterium tuberculosis infection

Immunological Reviews

Volumn 264, Issue 1, 2015, Pages 167-181

  Achkar, Jacqueline M ^a   Chan, John ^a   Casadevall, Arturo ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

Antibodies; B lymphocytes; Immunity; Immunoglobulins; Tuberculosis

Indexed keywords

B LYMPHOCYTE ANTIBODY; BCG VACCINE; BACTERIUM ANTIBODY;

ARTICLE; HUMAN; HUMORAL IMMUNITY; INFECTION CONTROL; LYMPHOCYTE; MACROPHAGE; NEUTROPHIL; PRIORITY JOURNAL; TUBERCULOSIS; VACCINATION; ANIMAL; B LYMPHOCYTE; CELL COMMUNICATION; CELLULAR IMMUNITY; HOST PATHOGEN INTERACTION; IMMUNOLOGY; INNATE IMMUNITY; METABOLISM; MICROBIOLOGY; MYCOBACTERIUM TUBERCULOSIS;

ANIMALS; ANTIBODIES, BACTERIAL; B-LYMPHOCYTES; CELL COMMUNICATION; HOST-PATHOGEN INTERACTIONS; HUMANS; IMMUNITY, CELLULAR; IMMUNITY, HUMORAL; IMMUNITY, INNATE; MYCOBACTERIUM TUBERCULOSIS; TUBERCULOSIS; TUBERCULOSIS VACCINES;

EID: 84923169950     PISSN: 01052896     EISSN: 1600065X     Source Type: Journal    
DOI: 10.1111/imr.12276     Document Type: Article

References (189)

1. World Health Organization. Global Tuberculosis Report 2014. Geneva, Switzerland: WHO, 2014. Available at: http://www.who.int/tb/publications/global_report/en/
2. Colditz GA, et al. Efficacy of BCG vaccine in the prevention of tuberculosis. Meta-analysis of the published literature. JAMA 1994;271:698-702.
3. Trunz BB, Fine P, Dye C. Effect of BCG vaccination on childhood tuberculous meningitis and miliary tuberculosis worldwide: a meta-analysis and assessment of cost-effectiveness. Lancet 2006;367:1173-1180.
4. Andersen P, Kaufmann SH. Novel vaccination strategies against tuberculosis. Cold Spring Harb Perspect Med 2014;4. doi: 10.1101/cshperspect.a018523.
5. Rook GA, Hernandez-Pando R. The pathogenesis of tuberculosis. Annu Rev Microbiol 1996;50:259-284.
6. Lewinsohn DA, Gold MC, Lewinsohn DM. Views of immunology: effector T cells. Immunol Rev 2011;240:25-39.
7. Ottenhoff TH. New pathways of protective and pathological host defense to mycobacteria. Trends Microbiol 2012;20:419-428.
8. Ottenhoff TH, Kaufmann SH. Vaccines against tuberculosis: where are we and where do we need to go? PLoS Pathog 2012;8:e1002607.
9. Sakai S, Mayer-Barber KD, Barber DL. Defining features of protective CD4 T cell responses to Mycobacterium tuberculosis. Curr Opin Immunol 2014;29:137-142.
10. Behar SM, Carpenter SM, Booty MG, Barber DL, Jayaraman P. Orchestration of pulmonary T cell immunity during Mycobacterium tuberculosis infection: immunity interruptus. Semin Immunol 2014;26:559-577.
11. Ernst JD. The immunological life cycle of tuberculosis. Nat Rev Immunol 2012;12:581-591.
12. Verrall AJ, Netea MG, Alisjahbana B, Hill PC, van Crevel R. Early clearance of Mycobacterium tuberculosis: a new frontier in prevention. Immunology 2014;141:506-513.
13. Cassidy JP, Martineau AR. Innate resistance to tuberculosis in man, cattle and laboratory animal models: nipping disease in the bud? J Comp Pathol 2014;151:291-308.
14. Natarajan K, Kundu M, Sharma P, Basu J. Innate immune responses to M. tuberculosis infection. Tuberculosis 2011;91:427-431.
15. Achkar JM, Casadevall A. Antibody-mediated immunity against tuberculosis: implications for vaccine development. Cell Host Microbe 2013;13:250-262.
16. Achkar JM, Chan J, Casadevall A. Role of B cells and antibodies in acquired immunity against mycobacterium tuberculosis. Cold Spring Harb Perspect Med 2014. doi: 10.1101/cshperspect.a018432.
17. Chan J, et al. The role of B cells and humoral immunity in Mycobacterium tuberculosis infection. Semin Immunol 2014;26:588-600.
18. Kozakiewicz L, Phuah J, Flynn J, Chan J. The role of B cells and humoral immunity in Mycobacterium tuberculosis infection. Adv Exp Med Biol 2013;783:225-250.
19. Casadevall A, Pirofski LA. A reappraisal of humoral immunity based on mechanisms of antibody-mediated protection against intracellular pathogens. Adv Immunol 2006;91:1-44.
20. Nimmerjahn F, Ravetch JV. Fcgamma receptors as regulators of immune responses. Nat Rev Immunol 2008;8:34-47.
21. Casadevall A, Pirofski LA. A new synthesis for antibody-mediated immunity. Nat Immunol 2012;13:21-28.
22. Casadevall A, Pirofski L. Insights into mechanisms of antibody-mediated immunity from studies with Cryptococcus neoformans. Curr Mol Med 2005;5:421-433.
23. Igietseme JU, Eko FO, He Q, Black CM. Antibody regulation of Tcell immunity: implications for vaccine strategies against intracellular pathogens. Exp Rev Vaccines 2004;3:23-34.
24. Wahid R, Simon R, Zafar SJ, Levine MM, Sztein MB. Live oral typhoid vaccine Ty21a induces cross-reactive humoral immune responses against Salmonella enterica serovar Paratyphi A and S. Paratyphi B in humans. Clin Vaccine Immunol 2012;19:825-834.
25. Wahid R, Zafar SJ, McArthur MA, Pasetti MF, Levine MM, Sztein MB. Live oral Salmonella enterica serovar Typhi vaccines Ty21a and CVD 909 induce opsonophagocytic functional antibodies in humans that cross-react with S. Paratyphi A and S. Paratyphi B. Clin Vaccine Immunol 2014;21:427-434.
26. Cowan C, Philipovskiy AV, Wulff-Strobel CR, Ye Z, Straley SC. Anti-LcrV antibody inhibits delivery of Yops by Yersinia pestis KIM5 by directly promoting phagocytosis. Infect Immun 2005;73:6127-6137.
27. Kumar D, Kirimanjeswara G, Metzger DW. Intranasal administration of an inactivated Yersinia pestis vaccine with interleukin-12 generates protective immunity against pneumonic plague. Clin Vaccine Immunol 2011;18:1925-1935.
28. Boyer JL, et al. Protective immunity against a lethal respiratory Yersinia pestis challenge induced by V antigen or the F1 capsular antigen incorporated into adenovirus capsid. Hum Gene Ther 2010;21:891-901.
29. Galen JE, et al. A bivalent typhoid live vector vaccine expressing both chromosomal and plasmid-encoded Y. pestis antigens fully protects against murine lethal pulmonary plague infection. Infect Immun 2015;83:161-172.
30. Li JS, Winslow GM. Survival, replication, and antibody susceptibility of Ehrlichia chaffeensis outside of host cells. Infect Immun 2003;71:4229-4237.
31. Li JS, et al. Outer membrane protein-specific monoclonal antibodies protect SCID mice from fatal infection by the obligate intracellular bacterial pathogen Ehrlichia chaffeensis. J Immunol 2001;166:1855-1862.
32. Gomez G, Adams LG, Rice-Ficht A, Ficht TA. Host-Brucella interactions and the Brucella genome as tools for subunit antigen discovery and immunization against brucellosis. Front Cell Infect Microbiol 2013;3:17.
33. Hoffmann EM, Houle JJ. Contradictory roles for antibody and complement in the interaction of Brucella abortus with its host. Crit Rev Microbiol 1995;21:153-163.
34. Winter AJ, Duncan JR, Santisteban CG, Douglas JT, Adams LG. Capacity of passively administered antibody to prevent establishment of Brucella abortus infection in mice. Infect Immun 1989;57:3438-3444.
35. Martinez E, Cantet F, Fava L, Norville I, Bonazzi M. Identification of OmpA, a Coxiella burnetii protein involved in host cell invasion, by multi-phenotypic high-content screening. PLoS Pathog 2014;10:e1004013.
36. Peng Y, Schoenlaub L, Elliott A, Mitchell WJ, Zhang G. Characterization of a lipopolysaccharide-targeted monoclonal antibody and its variable fragments as candidates for prophylaxis against the obligate intracellular bacterial pathogen coxiella burnetii. Infect Immun 2014;82:4530-4541.
37. Blander SJ, Horwitz MA. Vaccination with the major secretory protein of Legionella induces humoral and cell-mediated immune responses and protective immunity across different serogroups of Legionella pneumophila and different species of Legionella. J Immunol 1991;147:285-291.
38. Joller N, et al. Antibodies protect against intracellular bacteria by Fc receptor-mediated lysosomal targeting. Proc Natl Acad Sci USA 2010;107:20441-20446.
39. Weber SS, et al. Identification of protective B cell antigens of Legionella pneumophila. J Immunol 2012;189:841-849.
40. Agarwal S, Vasudhev S, DeOliveira RB, Ram S. Inhibition of the classical pathway of complement by meningococcal capsular polysaccharides. J Immunol 2014;193:1855-1863.
41. Bowe F, et al. Mucosal vaccination against serogroup B meningococci: induction of bactericidal antibodies and cellular immunity following intranasal immunization with NadA of Neisseria meningitidis and mutants of Escherichia coli heat-labile enterotoxin. Infect Immun 2004;72:4052-4060.
42. Hafner LM, Wilson DP, Timms P. Development status and future prospects for a vaccine against Chlamydia trachomatis infection. Vaccine 2014;32:1563-1571.
43. Khan SA, et al. Vaccination of koalas (Phascolarctos cinereus) with a recombinant chlamydial major outer membrane protein adjuvanted with poly I:C, a host defense peptide and polyphosphazine, elicits strong and long lasting cellular and humoral immune responses. Vaccine 2014;32:5781-5786.
44. Igietseme JU, Ward ME. Chlamydia update. Exp Rev Vaccines 2004;3:639-642.
45. Edelson BT, Unanue ER. Intracellular antibody neutralizes Listeria growth. Immunity 2001;14:503-512.
46. Nosanchuk JD, Steenbergen JN, Shi L, Deepe GS Jr, Casadevall A. Antibodies to a cell surface histone-like protein protect against Histoplasma capsulatum. J Clin Invest 2003;112:1164-1175.
47. Shi L, et al. A monoclonal antibody to Histoplasma capsulatum alters the intracellular fate of the fungus in murine macrophages. Eukaryot Cell 2008;7:1109-1117.
48. Cutts JC, Powell R, Agius PA, Beeson JG, Simpson JA, Fowkes FJ. Immunological markers of Plasmodium vivax exposure and immunity: a systematic review and meta-analysis. BMC Med 2014;12:150.
49. Deal C, Balazs AB, Espinosa DA, Zavala F, Baltimore D, Ketner G. Vectored antibody gene delivery protects against Plasmodium falciparum sporozoite challenge in mice. Proc Natl Acad Sci USA 2014;111:12528-12532.
50. Mizutani M, et al. Baculovirus-vectored multistage plasmodium vivax vaccine induces both protective and transmission-blocking immunities against transgenic rodent malaria parasites. Infect Immun 2014;82:4348-4357.
51. Sack BK, et al. Model for in vivo assessment of humoral protection against malaria sporozoite challenge by passive transfer of monoclonal antibodies and immune serum. Infect Immun 2014;82:808-817.
52. Wright KE, et al. Structure of malaria invasion protein RH5 with erythrocyte basigin and blocking antibodies. Nature 2014;515:427-430.
53. Gibson-Corley KN, et al. An in vitro model of antibody-enhanced killing of the intracellular parasite leishmania amazonensis. PLoS ONE 2014;9:e106426.
54. Gibson-Corley KN, Boggiatto PM, Mukbel RM, Petersen CA, Jones DE. A deficiency in the B cell response of C57BL/6 mice correlates with loss of macrophage-mediated killing of Leishmania amazonensis. Int J Parasitol 2010;40:157-161.
55. Vouldoukis I, et al. The killing of Leishmania major by human macrophages is mediated by nitric oxide induced after ligation of the Fc epsilon RII/CD23 surface antigen. Proc Natl Acad Sci USA 1995;92:7804-7808.
56. Kang H, Remington JS, Suzuki Y. Decreased resistance of B cell-deficient mice to infection with Toxoplasma gondii despite unimpaired expression of IFN-gamma, TNF-alpha, and inducible nitric oxide synthase. J Immunol 2000;164:2629-2634.
57. Vouldoukis I, Mazier D, Moynet D, Thiolat D, Malvy D, Mossalayi MD. IgE mediates killing of intracellular Toxoplasma gondii by human macrophages through CD23-dependent, interleukin-10 sensitive pathway. PLoS ONE 2011;6:e18289.
58. Glatman-Freedman A, Casadevall A. Serum therapy for tuberculosis revisited: reappraisal of the role of antibody-mediated immunity against Mycobacterium tuberculosis. Clin Microbiol Rev 1998;11:514-532.
59. Balu S, et al. A novel human IgA monoclonal antibody protects against tuberculosis. J Immunol 2011;186:3113-3119.
60. Chambers MA, Gavier-Widen D, Hewinson RG. Antibody bound to the surface antigen MPB83 of Mycobacterium bovis enhances survival against high dose and low dose challenge. FEMS Immunol Med Microbiol 2004;41:93-100.
61. Hamasur B, Haile M, Pawlowski A, Schroder U, Kallenius G, Svenson SB. A mycobacterial lipoarabinomannan specific monoclonal antibody and its F(ab') fragment prolong survival of mice infected with Mycobacterium tuberculosis. Clin Exp Immunol 2004;138:30-38.
62. Lopez Y, et al. Induction of a protective response with an IgA monoclonal antibody against Mycobacterium tuberculosis 16 kDa protein in a model of progressive pulmonary infection. Int J Med Microbiol 2009;299:447-452.
63. Pethe K, et al. The heparin-binding haemagglutinin of M. tuberculosis is required for extrapulmonary dissemination. Nature 2001;412:190-194.
64. Teitelbaum R, et al. A monoclonal antibody recognizing a surface antigen of Mycobacterium tuberculosis enhances host survival. Proc Natl Acad Sci USA 1998;95:15688-15693.
65. Williams A, et al. Passive protection with immunoglobulin A antibodies against tuberculous early infection of the lungs. Immunology 2004;111:328-333.
66. Buccheri S, et al. Prevention of the post-chemotherapy relapse of tuberculous infection by combined immunotherapy. Tuberculosis 2009;89:91-94.
67. Guirado E, et al. Passive serum therapy with polyclonal antibodies against Mycobacterium tuberculosis protects against post-chemotherapy relapse of tuberculosis infection in SCID mice. Microbes Infect 2006;8:1252-1259.
68. Olivares N, et al. The effect of the administration of human gamma globulins in a model of BCG infection in mice. Tuberculosis 2006;86:268-272.
69. Roy E, et al. Therapeutic efficacy of high-dose intravenous immunoglobulin in Mycobacterium tuberculosis infection in mice. Infect Immun 2005;73:6101-6109.
70. Costello AM, et al. Does antibody to mycobacterial antigens, including lipoarabinomannan, limit dissemination in childhood tuberculosis? Trans R Soc Trop Med Hyg 1992;86:686-692.
71. de Valliere S, Abate G, Blazevic A, Heuertz RM, Hoft DF. Enhancement of innate and cell-mediated immunity by antimycobacterial antibodies. Infect Immun 2005;73:6711-6720.
72. Hamasur B, et al. Mycobacterium tuberculosis arabinomannan-protein conjugates protect against tuberculosis. Vaccine 2003;21:4081-4093.
73. Kunnath-Velayudhan S, et al. Proteome-scale antibody responses and outcome of Mycobacterium tuberculosis infection in nonhuman primates and in tuberculosis patients. J Infect Dis 2012;206:697-705.
74. Maglione PJ, Xu J, Casadevall A, Chan J. Fc gamma receptors regulate immune activation and susceptibility during Mycobacterium tuberculosis infection. J Immunol 2008;180:3329-3338.
75. Maglione PJ, Xu J, Chan J. B cells moderate inflammatory progression and enhance bacterial containment upon pulmonary challenge with Mycobacterium tuberculosis. J Immunol 2007;178:7222-7234.
76. Vordermeier HM, Venkataprasad N, Harris DP, Ivanyi J. Increase of tuberculous infection in the organs of B cell-deficient mice. Clin Exp Immunol 1996;106:312-316.
77. Buccheri S, et al. IL-4 depletion enhances host resistance and passive IgA protection against tuberculosis infection in BALB/c mice. Eur J Immunol 2007;37:729-737.
78. Rodriguez A, et al. Role of IgA in the defense against respiratory infections IgA deficient mice exhibited increased susceptibility to intranasal infection with Mycobacterium bovis BCG. Vaccine 2005;23:2565-2572.
79. Tjarnlund A, et al. Polymeric IgR knockout mice are more susceptible to mycobacterial infections in the respiratory tract than wild-type mice. Int Immunol 2006;18:807-816.
80. Armstrong JA, Hart PD. Phagosome-lysosome interactions in cultured macrophages infected with virulent tubercle bacilli. Reversal of the usual nonfusion pattern and observations on bacterial survival. J Exp Med 1975;142:1-16.
81. Malik ZA, Denning GM, Kusner DJ. Inhibition of Ca(2+) signaling by Mycobacterium tuberculosis is associated with reduced phagosome-lysosome fusion and increased survival within human macrophages. J Exp Med 2000;191:287-302.
82. Suga M, Tanaka F, Muranaka H, Nishikawa H, Ando M. Effect of antibacterial antibody on bactericidal activities of superoxide and lysosomal enzyme from alveolar macrophages in rabbits. Respirology 1996;1:127-132.
83. Hetland G, Wiker HG, Hogasen K, Hamasur B, Svenson SB, Harboe M. Involvement of antilipoarabinomannan antibodies in classical complement activation in tuberculosis. Clin Diagn Lab Immunol 1998;5:211-218.
84. Carroll MV, Lack N, Sim E, Krarup A, Sim RB. Multiple routes of complement activation by Mycobacterium bovis BCG. Mol Immunol 2009;46:3367-3378.
85. Manivannan S, Rao NV, Ramanathan VD. Role of complement activation and antibody in the interaction between Mycobacterium tuberculosis and human macrophages. Indian J Exp Biol 2012;50:542-550.
86. Sutherland JS, et al. Differential gene expression of activating Fcgamma receptor classifies active tuberculosis regardless of human immunodeficiency virus status or ethnicity. Clin Microbiol Infect 2014;20:O230-O238.
87. Cliff JM, et al. Distinct phases of blood gene expression pattern through tuberculosis treatment reflect modulation of the humoral immune response. J Infect Dis 2013;207:18-29.
88. Mossalayi MD, et al. CD23 mediates antimycobacterial activity of human macrophages. Infect Immun 2009;77:5537-5542.
89. Encinales L, et al. Humoral immunity in tuberculin skin test anergy and its role in high-risk persons exposed to active tuberculosis. Mol Immunol 2010;47:1066-1073.
90. Glatman-Freedman A, Mednick AJ, Lendvai N, Casadevall A. Clearance and organ distribution of Mycobacterium tuberculosis lipoarabinomannan (LAM) in the presence and absence of LAM-binding immunoglobulin M. Infect Immun 2000;68:335-341.
91. Lancioni CL, et al. Mycobacterium tuberculosis lipoproteins directly regulate human memory CD4(+) T cell activation via Toll-like receptors 1 and 2. Infect Immun 2011;79:663-673.
92. Gaur RL, et al. LprG-mediated surface expression of lipoarabinomannan is essential for virulence of Mycobacterium tuberculosis. PLoS Pathog 2014;10:e1004376.
93. Prados-Rosales R, et al. Mycobacterial membrane vesicles administered systemically in mice induce a protective immune response to surface compartments of Mycobacterium tuberculosis. MBio 2014;5:e01921-e01914.
94. McClelland EE, Nicola AM, Prados-Rosales R, Casadevall A. antibody binding alters gene expression in Cryptococcus neoformans and directly modulates fungal metabolism. J Clin Invest 2010;120:1355-1361.
95. Yano M, Gohil S, Coleman JR, Manix C, Pirofski LA. Antibodies to Streptococcus pneumoniae capsular polysaccharide enhance pneumococcal quorum sensing. MBio 2011;2. doi: 10.1128/mBio.00176-11.
96. Connolly SE, Thanassi DG, Benach JL. Generation of a complement-independent bactericidal IgM against a relapsing fever Borrelia. J Immunol 2004;172:1191-1197.
97. Conti S, et al. Mycobactericidal activity of human natural, monoclonal, and recombinant yeast killer toxin-like antibodies. J Infect Dis 1998;177:807-811.
98. Taborda CP, Rivera J, Zaragoza O, Casadevall A. More is not necessarily better: prozone-like effects in passive immunization with IgG. J Immunol 2003;170:3621-3630.
99. Schwebach JR. The Carbohydrate Surface of M. tuberculosis: Antigenicity and Antibody Immunity. Bronx, NY: Albert Einstein College of Medicine, 2002.
100. Gonzalez-Juarrero M, Turner OC, Turner J, Marietta P, Brooks JV, Orme IM. Temporal and spatial arrangement of lymphocytes within lung granulomas induced by aerosol infection with Mycobacterium tuberculosis. Infect Immun 2001;69:1722-1728.
101. Tsai MC, et al. Characterization of the tuberculous granuloma in murine and human lungs: cellular composition and relative tissue oxygen tension. Cell Microbiol 2006;8:218-232.
102. Turner J, Frank AA, Brooks JV, Gonzalez-Juarrero M, Orme IM. The progression of chronic tuberculosis in the mouse does not require the participation of B lymphocytes or interleukin-4. Exp Gerontol 2001;36:537-545.
103. Ulrichs T, et al. Human tuberculous granulomas induce peripheral lymphoid follicle-like structures to orchestrate local host defence in the lung. J Pathol 2004;204:217-228.
104. Slight SR, et al. CXCR5(+) T helper cells mediate protective immunity against tuberculosis. J Clin Invest 2013;123:712-726.
105. Kahnert A, Hopken UE, Stein M, Bandermann S, Lipp M, Kaufmann SH. Mycobacterium tuberculosis triggers formation of lymphoid structure in murine lungs. J Infect Dis 2007;195:46-54.
106. Chakravarty SD, et al. Tumor necrosis factor blockade in chronic murine tuberculosis enhances granulomatous inflammation and disorganizes granulomas in the lungs. Infect Immun 2008;76:916-926.
107. Gordon S, Taylor PR. Monocyte and macrophage heterogeneity. Nat Rev Immunol 2005;5:953-964.
108. Martinez FO, Sica A, Mantovani A, Locati M. Macrophage activation and polarization. Front Biosci 2008;13:453-461.
109. Benoit M, Desnues B, Mege JL. Macrophage polarization in bacterial infections. J Immunol 2008;181:3733-3739.
110. Mantovani A, Allavena P, Sica A, Balkwill F. Cancer-related inflammation. Nature 2008;454:436-444.
111. Pollard JW. Trophic macrophages in development and disease. Nat Rev Immunol 2009;9:259-270.
112. Potian JA, Rafi W, Bhatt K, McBride A, Gause WC, Salgame P. Preexisting helminth infection induces inhibition of innate pulmonary anti-tuberculosis defense by engaging the IL-4 receptor pathway. J Exp Med 2011;208:1863-1874.
113. Wong SC, et al. Macrophage polarization to a unique phenotype driven by B cells. Eur J Immunol 2010;40:2296-2307.
114. Kozakiewicz L, et al. B cells regulate neutrophilia during Mycobacterium tuberculosis infection and BCG vaccination by modulating the interleukin-17 response. PLoS Pathog 2013;9:e1003472.
115. Kondratieva TK, Rubakova EI, Linge IA, Evstifeev VV, Majorov KB, Apt AS. B cells delay neutrophil migration toward the site of stimulus: tardiness critical for effective bacillus Calmette-Guerin vaccination against tuberculosis infection in mice. J Immunol 2010;184:1227-1234.
116. Corominas M, et al. B-lymphocytes and co-stimulatory molecules in Mycobacterium tuberculosis infection. Int J Tuberc Lung Dis 2004;8:98-105.
117. Hernandez J, et al. Low number of peripheral blood B lymphocytes in patients with pulmonary tuberculosis. Immunol Invest 2010;39:197-205.
118. Flynn JL. Lessons from experimental Mycobacterium tuberculosis infections. Microbes Infect 2006;8:1179-1188.
119. Achkar JM, Jenny-Avital ER. Incipient and subclinical tuberculosis: defining early disease states in the context of host immune response. J Infect Dis 2011;204(Suppl 4):S1179-S1186.
120. Schwander S, Dheda K. Human lung immunity against Mycobacterium tuberculosis: insights into pathogenesis and protection. Am J Respir Crit Care Med 2011;183:696-707.
121. Orme IM. Vaccines to prevent tuberculosis infection rather than disease: Physiological and immunological aspects. Tuberculosis (Edinb) 2014. in press; pii: S1472?9792(14)20550-6.
122. Bitsaktsis C, Babadjanova Z, Gosselin EJ. In vivo mechanisms involved in enhanced protection utilizing an FcR-targeted mucosal vaccine platform in a bacterial vaccine and challenge model. Infect Immun 2015;83:77-89.
123. Cole FS, Matthews WJ Jr, Rossing TH, Gash DJ, Lichtenberg NA, Pennington JE. Complement biosynthesis by human bronchoalveolar macrophages. Clin Immunol Immunopathol 1983;27:153-159.
124. Strunk RC, Eidlen DM, Mason RJ. Pulmonary alveolar type II epithelial cells synthesize and secrete proteins of the classical and alternative complement pathways. J Clin Invest 1988;81:1419-1426.
125. Coonrod JD, Yoneda K. Complement and opsonins in alveolar secretions and serum of rats with pneumonia due to Streptococcus pneumoniae. Rev Infect Dis 1981;3:310-322.
126. Giclas PC, King TE, Baker SL, Russo J, Henson PM. Complement activity in normal rabbit bronchoalveolar fluid. Description of an inhibitor of C3 activation. Am Rev Respir Dis 1987;135:403-411.
127. Watford WT, Ghio AJ, Wright JR. Complement-mediated host defense in the lung. Am J Physiol Lung Cell Mol Physiol 2000;279:L790-L798.
128. Kolb WP, Kolb LM, Wetsel RA, Rogers WR, Shaw JO. Quantitation and stability of the fifth component of complement (C5) in bronchoalveolar lavage fluids obtained from non-human primates. Am Rev Respir Dis 1981;123:226-231.
129. Gideon HP, Flynn JL. Latent tuberculosis: what the host "sees"? Immunol Res 2011;50:202-212.
130. Lawn SD, Wood R, Wilkinson RJ. Changing concepts of "latent tuberculosis infection" in patients living with HIV infection. Clin Dev Immunol 2011;2011. doi: 10.1155/2011/980594.
131. Barry CE 3rd, et al. The spectrum of latent tuberculosis: rethinking the biology and intervention strategies. Nat Rev Microbiol 2009;7:845-855.
132. Saunders BM, Britton WJ. Life and death in the granuloma: immunopathology of tuberculosis. Immunol Cell Biol 2007;85:103-111.
133. Davis JM, Ramakrishnan L. The role of the granuloma in expansion and dissemination of early tuberculous infection. Cell 2009;136:37-49.
134. Rubin EJ. The granuloma in tuberculosis-friend or foe? N Engl J Med 2009;360:2471-2473.
135. Russell DG, Cardona PJ, Kim MJ, Allain S, Altare F. Foamy macrophages and the progression of the human tuberculosis granuloma. Nat Immunol 2009;10:943-948.
136. Russo RT, Mariano M. B-1 cell protective role in murine primary Mycobacterium bovis bacillus Calmette-Guerin infection. Immunobiology 2010;215:1005-1014.
137. Grosset J. Mycobacterium tuberculosis in the extracellular compartment: an underestimated adversary. Antimicrob Agents Chemother 2003;47:833-836.
138. Hoff DR, et al. Location of intra- and extracellular M. tuberculosis populations in lungs of mice and guinea pigs during disease progression and after drug treatment. PLoS ONE 2011;6:e17550.
139. Casadevall A, Pirofski LA. The damage-response framework of microbial pathogenesis. Nat Rev Microbiol 2003;1:17-24.
140. Roca FJ, Ramakrishnan L. TNF dually mediates resistance and susceptibility to mycobacteria via mitochondrial reactive oxygen species. Cell 2013;153:521-534.
141. Knaul JK, et al. Lung-residing myeloid-derived suppressors display dual functionality in murine pulmonary tuberculosis. Am J Respir Crit Care Med 2014;190:1053-1066.
142. Centers for Disease C, Prevention. Tuberculosis associated with blocking agents against tumor necrosis factor-alpha-California, 2002-2003. MMWR Morb Mortal Wkly Rep 2004;53:683-686.
143. Haanaes OC, Bergmann A. Tuberculosis emerging in patients treated with corticosteroids. Eur J Respir Dis 1983;64:294-297.
144. Lee CH, Wang WJ, Lan RS, Tsai YH, Chiang YC. Corticosteroids in the treatment of tuberculous pleurisy. A double-blind, placebo-controlled, randomized study. Chest 1988;94:1256-1259.
145. Smego RA, Ahmed N. A systematic review of the adjunctive use of systemic corticosteroids for pulmonary tuberculosis. Int J Tuberc Lung Dis 2003;7:208-213.
146. Ntsekhe M, Wiysonge C, Volmink JA, Commerford PJ, Mayosi BM. Adjuvant corticosteroids for tuberculous pericarditis: promising, but not proven. QJM 2003;96:593-599.
147. Prasad K, Singh MB. Corticosteroids for managing tuberculous meningitis. Cochrane Database Syst Rev 2008;1:CD002244.
148. Thwaites GE, et al. Serial MRI to determine the effect of dexamethasone on the cerebral pathology of tuberculous meningitis: an observational study. Lancet Neurol 2007;6:230-236.
149. Thwaites GE, et al. Dexamethasone for the treatment of tuberculous meningitis in adolescents and adults. N Engl J Med 2004;351:1741-1751.
150. Dastur DK, Manghani DK, Udani PM. Pathology and pathogenetic mechanisms in neurotuberculosis. Radiol Clin North Am 1995;33:733-752.
151. Francois B, et al. Safety and pharmacokinetics of an anti-PcrV PEGylated monoclonal antibody fragment in mechanically ventilated patients colonized with Pseudomonas aeruginosa: a randomized, double-blind, placebo-controlled trial. Crit Care Med 2012;40:2320-2326.
152. Lu Q, et al. Pharmacokinetics and safety of panobacumab: specific adjunctive immunotherapy in critical patients with nosocomial Pseudomonas aeruginosa O11 pneumonia. J Antimicrob Chemother 2011;66:1110-1116.
153. Secher T, et al. The anti-Pseudomonas aeruginosa antibody Panobacumab is efficacious on acute pneumonia in neutropenic mice and has additive effects with meropenem. PLoS ONE 2013;8:e73396.
154. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. The IMpact-RSV Study Group. Pediatrics 1998;102:531-537.
155. American Academy of Pediatrics Committee on Infectious D, American Academy of Pediatrics Bronchiolitis Guidelines C. Updated guidance for palivizumab prophylaxis among infants and young children at increased risk of hospitalization for respiratory syncytial virus infection. Pediatrics 2014;134(Pt 1):415-420.
156. Scheid JF, et al. Broad diversity of neutralizing antibodies isolated from memory B cells in HIV-infected individuals. Nature 2009;458:636-640.
157. Klein F, et al. HIV therapy by a combination of broadly neutralizing antibodies in humanized mice. Nature 2012;492:118-122.
158. Barouch DH, et al. Therapeutic efficacy of potent neutralizing HIV-1-specific monoclonal antibodies in SHIV-infected rhesus monkeys. Nature 2013;503:224-228.
159. Chan AC, Carter PJ. Therapeutic antibodies for autoimmunity and inflammation. Nat Rev Immunol 2010;10:301-316.
160. Weiner LM, Surana R, Wang S. Monoclonal antibodies: versatile platforms for cancer immunotherapy. Nat Rev Immunol 2010;10:317-327.
161. Saylor C, Dadachova E, Casadevall A. Monoclonal antibody-based therapies for microbial diseases. Vaccine 2009;27(Suppl 6):G38-G46.
162. Chow SK, Smith C, MacCarthy T, Pohl MA, Bergman A, Casadevall A. Disease enhacing antibodies improve the efficacy of bacterial toxin-neutralizing antibodies. Cell Host Microbe 2013;13:417-428.
163. Pohl MA, Rivera J, Nakouzi A, Chow SK, Casadevall A. Combinations of antibodies to anthrax toxin manifest emergent properties in neutralization assays. Infect Immun 2013;81:1880-1888.
164. Rawool DB, et al. Utilization of Fc receptors as a mucosal vaccine strategy against an intracellular bacterium, Francisella tularensis. J Immunol 2008;180:5548-5557.
165. Iglesias BV, et al. Multiple mechanisms mediate enhanced immunity generated by monoclonal antibody-inactivated F. tularensis immunogen. Immunol Cell Biol 2013;91:139-148.
166. Moore T, et al. Fc receptor-mediated antibody regulation of T cell immunity against intracellular pathogens. J Infect Dis 2003;188:617-624.
167. Feldmesser M, Casadevall A. Effect of serum IgG1 to Cryptococcus neoformans glucuronoxylomannan on murine pulmonary infection. J Immunol 1997;158:790-799.
168. Shapiro S, et al. Immunoglobulin G monoclonal antibodies to Cryptococcus neoformans protect mice deficient in complement component C3. Infect Immun 2002;70:2598-2604.
169. Feldmesser M, Mednick A, Casadevall A. Antibody-mediated protection in murine Cryptococcus neoformans infection is associated with pleotrophic effects on cytokine and leukocyte responses. Infect Immun 2002;70:1571-1580.
170. Martinez LR, Moussai D, Casadevall A. Antibody to Cryptococcus neoformans glucuronoxylomannan inhibits the release of capsular antigen. Infect Immun 2004;72:3674-3679.
171. Beenhouwer DO, Yoo EM, Lai CW, Rocha MA, Morrison SL. Human immunoglobulin G2 (IgG2) and IgG4, but not IgG1 or IgG3, protect mice against Cryptococcus neoformans infection. Infect Immun 2007;75:1424-1435.
172. Cordero RJ, et al. Antibody binding to Cryptococcus neoformans impairs budding by altering capsular mechanical properties. J Immunol 2013;190:317-323.
173. Glatman-Freedman A, et al. Antigenic evidence of prevalence and diversity of Mycobacterium tuberculosis arabinomannan. J Clin Microbiol 2004;42:3225-3231.
174. Chang-hong S, Xiao-wu W, Hai Z, Ting-fen Z, Li-Mei W, Zhi-kai X. Immune responses and protective efficacy of the gene vaccine expressing Ag85B and ESAT6 fusion protein from Mycobacterium tuberculosis. DNA Cell Biol 2008;27:199-207.
175. Giri PK, Verma I, Khuller GK. Enhanced immunoprotective potential of Mycobacterium tuberculosis Ag85 complex protein based vaccine against airway Mycobacterium tuberculosis challenge following intranasal administration. FEMS Immunol Med Microbiol 2006;47:233-241.
176. Grover A, Ahmed MF, Singh B, Verma I, Sharma P, Khuller GK. A multivalent combination of experimental antituberculosis DNA vaccines based on Ag85B and regions of difference antigens. Microbes Infect 2006;8:2390-2399.
177. Huygen K, et al. Immunogenicity and protective efficacy of a tuberculosis DNA vaccine. Nat Med 1996;2:893-898.
178. Kohama H, et al. Mucosal immunization with recombinant heparin-binding haemagglutinin adhesin suppresses extrapulmonary dissemination of Mycobacterium bovis bacillus Calmette-Guerin (BCG) in infected mice. Vaccine 2008;26:924-932.
179. Niu H, et al. Construction and evaluation of a multistage Mycobacterium tuberculosis subunit vaccine candidate Mtb10.4-HspX. Vaccine 2011;29:9451-9458.
180. Palma C, et al. The LTK63 adjuvant improves protection conferred by Ag85B DNA-protein prime-boosting vaccination against Mycobacterium tuberculosis infection by dampening IFN-gamma response. Vaccine 2008;26:4237-4243.
181. Teixeira FM, et al. DNA vaccine using Mycobacterium bovis Ag85B antigen induces partial protection against experimental infection in BALB/c mice. Clin Vaccine Immunol 2006;13:930-935.
182. Xue T, et al. RNA encoding the MPT83 antigen induces protective immune responses against Mycobacterium tuberculosis infection. Infect Immun 2004;72:6324-6329.
183. Cruz AT, Starke JR. Clinical manifestations of tuberculosis in children. Paediatr Respir Rev 2007;8:107-117.
184. Donald PR, Marais BJ, Barry CE 3rd. Age and the epidemiology and pathogenesis of tuberculosis. Lancet 2010;375:1852-1854.
185. Beyazova U, Rota S, Cevheroglu C, Karsligil T. Humoral immune response in infants after BCG vaccination. Tuber Lung Dis 1995;76:248-253.
186. Boggian K, Fierz W, Vernazza PL. Infrequent detection of lipoarabinomannan antibodies in human immunodeficiency virus-associated mycobacterial disease. Swiss HIV Cohort Study. J Clin Microbiol 1996;34:1854-1855.
187. Dayal R, et al. Serological diagnosis of tuberculosis. Indian J Pediatr 2008;75:1219-1221.
188. Gupta S, Bhatia R, Datta KK. Serological diagnosis of childhood tuberculosis by estimation of mycobacterial antigen 60-specific immunoglobulins in the serum. Tuber Lung Dis 1997;78:21-27.
189. Sada E, Ferguson LE, Daniel TM. An ELISA for the serodiagnosis of tuberculosis using a 30, 000-Da native antigen of Mycobacterium tuberculosis. J Infect Dis 1990;162:928-931.